Analysts Set Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) Price Target at $34.42

Shares of Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) have earned an average rating of “Moderate Buy” from the ten analysts that are currently covering the company, Marketbeat.com reports. One research analyst has rated the stock with a hold rating and nine have issued a buy rating on the company. The average 12 month price objective among brokerages that have covered the stock in the last year is $34.42.

Several research analysts have weighed in on the company. JPMorgan Chase & Co. increased their price objective on Syndax Pharmaceuticals from $31.00 to $34.00 and gave the stock an “overweight” rating in a research report on Wednesday, March 20th. Scotiabank cut Syndax Pharmaceuticals from a “sector outperform” rating to a “sector perform” rating and lowered their price objective for the stock from $36.00 to $23.00 in a research report on Wednesday, January 31st. HC Wainwright reiterated a “buy” rating and set a $41.00 price objective on shares of Syndax Pharmaceuticals in a research report on Friday. Finally, StockNews.com upgraded Syndax Pharmaceuticals to a “sell” rating in a research report on Friday, January 19th.

Institutional Trading of Syndax Pharmaceuticals

Large investors have recently bought and sold shares of the business. BVF Inc. IL acquired a new stake in shares of Syndax Pharmaceuticals during the fourth quarter valued at about $40,519,000. Avoro Capital Advisors LLC boosted its stake in shares of Syndax Pharmaceuticals by 65.2% during the fourth quarter. Avoro Capital Advisors LLC now owns 4,222,222 shares of the company’s stock valued at $91,242,000 after purchasing an additional 1,666,667 shares in the last quarter. Kynam Capital Management LP boosted its stake in shares of Syndax Pharmaceuticals by 41.5% during the fourth quarter. Kynam Capital Management LP now owns 5,660,000 shares of the company’s stock valued at $122,313,000 after purchasing an additional 1,660,000 shares in the last quarter. Franklin Resources Inc. acquired a new stake in shares of Syndax Pharmaceuticals during the fourth quarter valued at about $29,236,000. Finally, Avidity Partners Management LP boosted its stake in shares of Syndax Pharmaceuticals by 40.0% during the fourth quarter. Avidity Partners Management LP now owns 3,950,000 shares of the company’s stock valued at $85,360,000 after purchasing an additional 1,129,000 shares in the last quarter.

Syndax Pharmaceuticals Trading Up 2.4 %

SNDX opened at $21.06 on Monday. Syndax Pharmaceuticals has a 1-year low of $11.22 and a 1-year high of $25.34. The stock’s fifty day simple moving average is $22.67 and its 200 day simple moving average is $19.56. The stock has a market cap of $1.79 billion, a PE ratio of -7.11 and a beta of 1.03.

Syndax Pharmaceuticals (NASDAQ:SNDX) last posted its quarterly earnings data on Tuesday, February 27th. The company reported ($1.00) earnings per share for the quarter, missing the consensus estimate of ($0.99) by ($0.01). During the same period in the previous year, the company posted ($0.62) earnings per share. Equities analysts forecast that Syndax Pharmaceuticals will post -3.7 earnings per share for the current year.

About Syndax Pharmaceuticals

Syndax Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops therapies for the treatment of cancer. Its lead product candidates are revumenib, a potent, selective, small molecule inhibitor of the menin-MLL binding interaction for the treatment of KMT2A rearranged, acute leukemias, and solid tumor; and SNDX-6352 or axatilimab, a monoclonal antibody that blocks the colony stimulating factor 1, or CSF-1 receptor for the treatment of patients with chronic graft versus host disease (cGVHD) and idiopathic pulmonary fibrosis (IPF).